Maynard Um
-
-
-
-
-
-
-
Barclays Downgrades Nuvalent (NUVL) to Equalweight
-
-
-
-
-
-
-
Wedbush Downgrades Nuvalent (NUVL) to Neutral
-
-
-
-
-
-
-
Nuvalent (NUVL) Reiterated at Overweight by Cantor Fitzgerald
-
-
-
-
-
-
-
Stifel: 'We believe these AACR datasets flex NUVL's medicinal chemistry prowess'
-
-
-
-
-
-
-
Nuvalent reports Q4 2025 results, awaits FDA decision on zidesamtinib
-
-
-
-
-
-
-
FDA accepts Nuvalent drug application for lung cancer treatment
-
-
-
-
-
-
-
Nuvalent reports trial results for ALK lung cancer drug neladalkib
-
406,556 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

